Insights into Zura Bio's First Quarter Financial Results and Future Outlook
HENDERSON, Nev., May 09, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its first quarter 2024 financial results, and recent business highlights.
Director Amit Munshi has recently increased his stake in Zura Bio Ltd (NASDAQ:ZURA) by purchasing 159,744 shares of the company, as per the SEC Filing dated 2024-04-22.